Bluejay Diagnostics (NASDAQ:BJDX) Announces Earnings Results, Beats Expectations By $3,518.28 EPS

Bluejay Diagnostics (NASDAQ:BJDX) posted its earnings results on Thursday. The company reported ($1.72) EPS for the quarter, beating analysts’ consensus estimates of ($3,520.00) by $3,518.28, FiscalAI reports.

Bluejay Diagnostics Stock Performance

BJDX stock traded up $0.23 during midday trading on Friday, reaching $2.84. The stock had a trading volume of 11,906 shares, compared to its average volume of 535,918. The stock has a market cap of $3.18 million, a PE ratio of -0.10 and a beta of 0.92. The firm has a fifty day simple moving average of $3.09 and a two-hundred day simple moving average of $7.00. Bluejay Diagnostics has a 52-week low of $1.84 and a 52-week high of $28.00.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. Wall Street Zen downgraded Bluejay Diagnostics from a “hold” rating to a “sell” rating in a research report on Monday, September 14th. Weiss Ratings reissued a “sell (e+)” rating on shares of Bluejay Diagnostics in a research report on Monday, September 21st. One analyst has rated the stock with a Sell rating. According to MarketBeat, the stock has a consensus rating of “Sell”.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc. is a medical technology company focused on developing rapid, point-of-care diagnostic testing solutions. The company’s technology is designed to provide healthcare professionals with timely information from blood samples, supporting clinical decision-making in settings where conventional laboratory testing may take longer. Its primary product is the Symphony system, a diagnostic platform consisting of an analyzer and disposable test cartridges. The platform is intended to measure biomarkers in whole blood and is being developed for applications including the assessment and management of serious medical conditions such as sepsis and other critical-care situations.